Background: Although sarcomas account for only 1% of all solid tumours, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the limited number of registered or active drugs for these diseases. To help in patient selection, we evaluated the utility of the predictive Royal Marsden Score which had been derived in carcinoma patients. In addition, we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials.
help in patient selection, we evaluated the utility of the predictive Royal Marsden Score which had been derived in carcinoma patients. In addition, we analysed efficacy and toxicity regarding the sarcoma population enrolled in phase I trials. Results: One hundred and seventy-eight patients diagnosed with advanced sarcoma or other mesenchymal tumours were identified and accounted for 217 phase I trial participations during the study period. Histological type, class of drug, number of metastatic sites, high serum lactate dehydrogenase activity (LDH), low albumin and high white blood cell count were independent prognostic factors. Poor performance status (PS), liver metastases and high leucocyte count were associated with increased risk of early death. The class of drug used was the strongest predictor of progression-free survival (PFS) duration, inhibitors of angiogenesis and histone deacetylase giving the best results. Poor PS, high serum LDH and low lymphocyte count correlated with shorter PFS. In this heterogeneous population, PFS with investigational agents appeared comparable with that previously published for patients receiving standard treatments beyond first line.
Patients and methods:
Conclusion: Prognostic factors in sarcoma patients do not differ from a broader phase I population. Efficacy measures suggest that some patients with sarcoma derive benefit from therapy in this setting which could therefore be considered for patients with no remaining standard therapeutic option. Key words: sarcoma, phase I, clinical trial, targeted therapies introduction Sarcomas are a heterogeneous group of malignant tumours originating from mesenchymal tissue. In the setting of advanced disease, most patients are treated with doxorubicin-based chemotherapy. The prognosis of patients with advanced sarcomas is poor and has seen little improvement if any over the last 20 years [1] . Few cytotoxic drugs are specifically approved for the management of sarcomas, and some subtypes are recognized as chemotherapy resistant. The advent of molecularly targeted anti-cancer therapeutics has drastically changed the clinical outcome in a few well-defined sarcoma subtypes but these subgroups remain a minority [2] [3] [4] [5] .
While sarcomas represent only 1.5% of all cancer cases, patients with advanced sarcomas often represent over 10% of patients enrolled in phase I trials, reflecting the limited number of therapeutic options available for these patients. Their prognosis and prognostic factors in phase I studies have only rarely been described. In this project, we used the European Drug Development Network (EDDN) database comprising 2182 patients treated in phase I trials to describe the outcome of sarcoma patients entering phase I trials.
patients and methods

patient selection
This study considered patients with a diagnosis of bone or soft tissue sarcoma (STS) included in the EDDN database, an international consortium involving 14 oncology drug development units which was described elsewhere [6] . This database includes a total of 2182 eligible consecutive phase I trial patients treated between January 2005 to December 2007, 217 (10%) of which had a diagnosis of sarcoma. Other eligibility criteria for entry in the EDDN database were previously described [6] . All patients included in this analysis gave informed consent to take part in phase I trials, and all studies were approved by local institutional review boards.
statistical analysis
Prognostic factors validated as continuous variables were transformed into binomial variables. Cut-offs for conversions were chosen on the basis of considerations of the standard reference or median values. Twenty-eight different histological subgroups were found and in an effort of simplification these histological groups were categorized as STSs, high-grade bone sarcomas (Ewing sarcoma and osteosarcoma), other bone tumours (chordomas and chondrosarcomas), gastrointestinal stromal tumours (GIST) and locally aggressive tumours (desmoid tumours and dermatofibrosarcoma protuberans). The Royal Marsden Hospital (RMH) score was based on serum lactate dehydrogenase activity (LDH), serum albumin level and number of metastatic sites and ranged from 0 to 3 as previously described [7] . Treatments were grouped as cytotoxics (CTA) versus molecularly targeted agents (MTA), and single agent versus combinations. Treatments based on MTA were further subgrouped according to the supposed mechanism of action of the drug (Table 1 ). In addition, we calculated the time per treatment index (TPTi), a log ratio of the time interval between diagnosis of advanced/metastatic cancer and phase I trial entry divided by the number of lines of systemic treatment, by using [log (time + 1/treatments + 1)] [6] .
Two survival analyses were carried out: first, an analysis of prognostic factors where overall survival (OS) was calculated from the date of treatment start in the first participation in a phase I trial to the date of death, or censored at last follow-up; and second, an analysis of factors predicting 90-day mortality. For 90-day mortality, OS was calculated as previously stated and patients surviving beyond 90 days were censored at 90 days.
Finally, progression-free survival (PFS) was calculated from the date of treatment start to the date of progression or death, or censored at last followup for patients surviving without disease progression. Variables are depicted in supplementary Table S1 , available at Annals of Oncology online.
results
patient baseline characteristics
We identified 178 patients. The RMH (London, UK), the Institut Gustave Roussy (Paris, France) and the Centre Oscar Lambret (Lille, France) provided 48, 25 and 23 patients and therefore collectively accounted for almost 54% of the whole cohort. Most patients (n = 149) participated in a single trial but 22, 4 and 3 patients participated in 2, 3 and 4 successive phase I trials, respectively, adding up to a total of 217 phase I participations in the study period. Patients' characteristics are described in Table 2 (12.4%) had aggressive bone sarcomas, 13 (7.3%) had other bone tumours, 15 (8.4%) had GIST and 3 had locally aggressive tumours (aggressive fibromatosis, n = 2 and dermatofibrosarcoma protuberans, n = 1). Among 125 patients with STS, the most common histological subtypes were leiomyosarcoma (n = 34, 27.2%), followed by liposarcoma (n = 16, 12.8%, including 2 patients with myxoid liposarcomas) and malignant fibrous histocytoma (MFH) (n = 15, 12%). For 25 patients (20%), the diagnosis was STS not otherwise specified.
treatment characteristics
These 178 patients made up 217 single participations in phase I trials, most of which (n = 115, 53.0%) were in trials of single MTAs. Forty-nine participations (22.6%) were in trials of MTA combined with chemotherapy and 43 in trials of novel CTA either alone (n = 35, 16.1%) or in combination (n = 8, 3.7%, Table 1 ). Single-agent CTAs (19 of 35, 54%) were in most cases platinum derivatives, while combinations of CTAs were more heterogeneous. The majority of trials investigating single-agent MTA involved either inhibitors of angiogenesis (42 of 115, 37%) or inhibitors of IGF1R (17 of 115, 15%) ( Table 1 ). The median number of prior lines of therapy was 2 (range 0-9) and 22 patients (12%) received treatment in a phase I trial as their first line of systemic therapy. The majority of patients (n = 144, 66%) had an RMH score of 0 or 1. The RMH score could not be Figure S1 , available at Annals of Oncology online). In multivariate analysis, histological group, number of metastatic sites, drug class, LDH, albumin and WBC count remained significantly associated with OS (Table 3) .
factors predicting 90-day mortality
Thirty of 178 patients (17%) died within the first 90 days on study, and the cause of death was disease progression in all cases. In univariate analysis, seven variables met the prespecified threshold of P ≥ 0.1 to be incorporated in the multivariate analysis: PS, presence of liver metastases, bone metastases, number of previous lines of therapy, TPTi, RMH score and WBC count. Only three variables remained significant in the multivariate model: presence of liver metastases, more than four lines of prior therapy and high leucocyte count were all predictive of death within the first 90 days on study (Table 4) .
response rate and progression-free survival
Fifteen patients (6.9%) were not assessable for response. No complete responses were noted, but six patients had a confirmed RECIST (version 1.0) partial response (PR) (response rate = 3%). These six patients and their treatments are described in Table S2 , available at Annals of Oncology online). When analysing outcome per type of trial, there was a statistically significant difference between CTA and MTA, favouring MTA. In univariate analysis, the type of drug was the strongest predictor of PFS, and remained significant in multivariate analysis (Table 6 ). Factors associated with increased risk of progression in the multivariate model included poorer PS, lymphocyte count <0.7 × 10 9 /l and LDH above the upper limit of normal.
discussion
In this study, we sought to analyse the outcome of patients with advanced sarcomas entering phase I trials. The rationale for such an analysis is that sarcoma may differ in behaviour from carcinomas and may represent up to 10% of patients enrolled in phase I trials. Also, we hypothesized that clinical and biological criteria that may be used for the selection of patients (i.e. those predicting a survival of <90 days) may be different for patients with sarcomas. Overall, the outcome of patients with sarcomas entering phase I trials, as measured by OS, 90-day mortality and PFS, appears similar to that reported for the general phase I population although the response rate in our analysis is somewhat lower than previously reported [6] [7] [8] . Median OS was 39.4 weeks (95% CI 27.4-51.4) which is comparable with the 38.6 weeks (95% CI 36.0-41.1 weeks) reported by Olmos et al. in the 1929 patients from the whole EDDN database. Similarly, the 90-day mortality rate in patients with sarcoma (17%) is in line with previously published Hazard ratios indicate increased (>1) or lowered (<1) risk of progression. ULN, upper limit of normal; WBC, white blood cell. data, suggesting that 15%-20% of patients entering phase I trials die within 90 days of study entry study [7] . The clinical variables that were associated with OS were similar to those identified by Arkenau et al. [7] further confirmed by Olmos et al. [6] and which comprise the RMH score, as well as other previously described variables such as performance status. The finding that the type of treatment may be associated with OS in the setting of phase I trials is intriguing but should be interpreted with caution as the number of patients treated with each class of agent is low and an interaction between the type of treatment and other prognostic factors may be a source of confusion. Interestingly, variables associated with early death were somewhat different from those predicting OS and included presence of liver metastases, number of previous lines of therapy and high leucocyte count. These factors are also associated with more advanced disease, higher tumour burden and/or rapid tumour growth and some of them (liver metastases) were previously associated with poor prognosis in patients with STS [9] . Our data also suggest that sarcoma patient derive some clinical benefit from phase I participation. Indeed, although anti-tumour activity is not the primary focus of these trials, the hope of therapeutic benefit remains the main reason for patient's participation in phase I trials [10, 11] . The response rate in this subgroup of patients was low overall, but the value of objective response in the assessment of agents for sarcomas has been debated because it does not accurately predict clinical benefit [12] [13] [14] . Hence, the 3-month and 6-month PFS rates were 33.5% and 16.9%, and these values were not statistically different from the 40% and 14% reported for agents considered to be active in second-line trials of sarcomas in the EORTC database analysis by Van Glabbeke et al. [15] . Of note, the analysis by van Glabbeke et al. was based on other criteria for response assessment (World Health Organization criteria) and used historical data generated long before the collection of data in this phase I series.
Jones et al. have previously reported on the outcome of sarcoma patients entering phase I trials [16] . Overall, and despite the fact that this series covered a larger time-window (10 years as opposed to 3 years in our series), their finding and conclusions are similar to ours (response rate 2.2%, 3-and 6-month nonprogression rate of 31.5% and 11.0%, respectively), reflecting the limited activity of most agents in sarcomas. This limited activity is nevertheless comparable with that observed in carcinoma patients entering phase I trials and also to older cytotoxic drugs available for the treatment of patients with advanced sarcomas [15] . As previously mentioned response by itself is only of limited value in the assessment of newer agents in sarcomas [12] [13] [14] and the most adequate surrogate end point for efficacy in this population remains to be defined.
In conclusion, prognostic factors for patients with advanced sarcomas entering phase I trials appear similar to those previously described for the general phase I oncology population. These trials appear to provide some degree of benefit in terms of disease control in a proportion of patients, at least compared with other therapeutic options available for this patient population. 
